These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25389307)

  • 21. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.
    Vicenti I; Falasca F; Sticchi L; Bruzzone B; Turriziani O; Zazzi M
    J Clin Virol; 2016 Mar; 76():20-3. PubMed ID: 26802683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates.
    Liberti A; Raddi A; Cuomo N
    Infez Med; 2016 Dec; 24(4):272-277. PubMed ID: 28011961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simeprevir: a macrocyclic HCV protease inhibitor.
    Talwani R; Heil EL; Gilliam BL; Temesgen Z
    Drugs Today (Barc); 2013 Dec; 49(12):769-79. PubMed ID: 24524095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
    Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
    J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.
    Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus genotypes in Tirana, Albania.
    Haldeda M; Baume J; Tamalet C; Bizhga M; Colson P
    Int J Infect Dis; 2014 Jan; 18():90-3. PubMed ID: 24169401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France.
    Hajji H; Aherfi S; Motte A; Ravaux I; Mokhtari S; Ruiz JM; Poizot-Martin I; Tourres C; Tivoli N; Gérolami R; Tamalet C; Colson P
    J Med Virol; 2015 Nov; 87(11):1921-33. PubMed ID: 25959702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease.
    Peres-da-Silva A; Antunes D; Quintanilha Torres AL; Caffarena ER; Lampe E
    Viruses; 2019 Jul; 11(8):. PubMed ID: 31366046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2014 Aug; 86(8):1314-22. PubMed ID: 24797623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simeprevir approved for hepatitis C virus infection.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(1):6. PubMed ID: 24352170
    [No Abstract]   [Full Text] [Related]  

  • 39. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
    Khera T; Todt D; Vercauteren K; McClure CP; Verhoye L; Farhoudi A; Bhuju S; Geffers R; Baumert TF; Steinmann E; Meuleman P; Pietschmann T; Brown RJ
    Antiviral Res; 2017 Mar; 139():129-137. PubMed ID: 28062191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.